Is Agen a good investment?
Agenus has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Why is Agen stock down?
Agenus (AGEN) has been beaten down lately with too much selling pressure. While the stock has lost 33.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.
Will AGEN stock go up?
The 3 analysts offering 12-month price forecasts for Agenus Inc have a median target of 8.00, with a high estimate of 14.00 and a low estimate of 7.00. The median estimate represents a +426.32% increase from the last price of 1.52.
What kind of company is AGEN?
immuno-oncology company
Company Information Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer.
Why is agenus stock going up?
In response to the impressive clinical progress of Agenus’ anti-cancer checkpoint inhibitor platform, Wainwright raised its 12-month price target on the biotech’s shares to $14 ahead of the opening bell this morning.
What kind of company is Agen?
When did Agen go public?
The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN.
Who owns agenus?
Top 10 Owners of Agenus Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 6.63% | 17,052,432 |
| Deep Track Capital LP | 5.92% | 15,229,187 |
| BlackRock Fund Advisors | 5.63% | 14,486,277 |
| Oracle Investment Management, Inc… | 3.54% | 9,106,132 |
What is going on with agenus?
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates Agenus (AGEN) delivered earnings and revenue surprises of -62.50% and 46.30%, respectively, for the quarter ended December 2021.
Is agenus a good stock to buy 2021?
We therefore hold a negative evaluation of this stock.
What is Agen agenus?
Agenus discovers, manufactures and develops immuno-oncology products. The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to deliver curative patient outcomes.
What’s happened to Agenus stock in November?
November has been brutal for biotech stocks. Agenus’ shares have been on a downward spiral ever since the FDA requested the company withdraw its BLA for the checkpoint inhibitor balstilimab last month.
Is it a good time to sell my Agen shares?
It’s a very risky time to sell any AGEN shares. We have a lot going on. Different QS21 collaboration s could move our stock and 1181 deals are nearby! Plus other possibiluties.
Will Agenus (Agen) go long in 5 days?
Happy Trading! options trading that AGEN will go long around 3.25 earnings in 5 days trade invalid around 2.80 or personal stop loss Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases.
What is the mechanism of action of agen1571 antibody?
Conclusion: AGEN1571 is a novel high-affinity ILT2 antagonist antibody that effectively antagonizes ILT2 to enhance T cell, NK cell, NKT cell, and myeloid activity. These data support clinical development of AGEN1571 as a therapeutic agent for patients with solid tumors.